Lv2
142 积分 2023-07-16 加入
Development and therapeutic potential of DNA-dependent protein kinase inhibitors
10天前
已完结
58 (PB046): Tumor-agnostic efficacy and safety of lirafugratinib, a highly selective FGFR2 inhibitor, in patients (pts) with advanced solid tumors with FGFR2 fusions or rearrangements (f/r): the ReFocus study
14天前
已关闭
Overcoming tyrosine kinase inhibitor resistance in lung cancer brain metastasis with CTLA4 blockade
17天前
已完结
Overcoming tyrosine kinase inhibitor resistance in lung cancer brain metastasis with CTLA4 blockade
24天前
已完结
Targeting DNA-PK in cancer
1个月前
已完结
Generation of Monoclonal Antibody Targeting Fibroblast Growth Factor Receptor 3
1个月前
已完结
ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response
4个月前
已完结
Targeting DNA-PK in cancer
4个月前
已完结
Obesity induces PD-1 on macrophages to suppress anti-tumour immunity
4个月前
已完结
Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations
6个月前
已完结
皖公网安备34019202002308
